Phase III Trial Initiated for Radioimmunotherapy Zevalin Against DLBCL
Spectrum Pharmaceuticals, makers of the radioimmunotherapy treatment Zevalin, have announced the initiation of a Phase III clinical trial of Zevalin in patients over the age of 60 who have been diagnosed with diffuse large B-cell lymphoma (DLBCL).
The so-called ZEST trial will have as its primary end point overall survival.
The ZEST trial will test the efficacy of the Zevalin therapeutic regimen against the current gold standard in diffuse large B-cell lymphoma, R-CHOP combination chemotherapy.
In prior Phase II trials, when Zevalin was given to DLBCL patients as consolidation therapy following R-CHOP, it showed a 5-year overall survival rate of 84% and a 5-year progression-free survival rate of 75%.
In fact, adding Zevalin after R-CHOP actually boosted overall survival in DLBCL patients by 15% compared to those patients who received R-CHOP and no consolidation therapy.
Currently, Zevalin is approved for a specific subset of patients with indolent non-Hodgkin's lymphomas. A successful Phase III trial could win the company marketing approval for Zevalin as therapy against more aggressive B-cell lymphomas.
Source: Reuters
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
